Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus CARVEDILOL PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus CARVEDILOL PHOSPHATE.
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER vs CARVEDILOL PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Competitive beta-blocker with alpha1-blocking activity; decreases cardiac output, reduces peripheral vascular resistance.
Intravenous: For stable patients, an initial loading dose of 500 mcg/kg/min over 1 minute followed by a maintenance infusion of 50 mcg/kg/min for 4 minutes; if response is inadequate, increase maintenance infusion to 100 mcg/kg/min and repeat loading dose after 10 minutes. Titrate in 50 mcg/kg/min increments up to 200 mcg/kg/min. For intraoperative and postoperative use, see full prescribing information.
6.25 mg orally twice daily, titrated up to a maximum of 25 mg twice daily for heart failure; 12.5 mg orally once daily for hypertension, titrated to 25-50 mg daily.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 8–10 minutes). Clinically, the half-life is consistent with rapid offset of effect upon discontinuation; steady state is achieved within 30 minutes of continuous infusion.
7-10 hours (terminal elimination half-life); clinical context: supports twice-daily dosing for sustained beta-blockade.
Primarily metabolized by red blood cell esterases; <1% excreted unchanged in urine. Elimination is not dependent on renal or hepatic function.
Primarily hepatic metabolism (CYP2D6 and CYP2C9) followed by biliary excretion into feces; ~60% fecal elimination as metabolites, ~16% renal elimination of unchanged drug plus metabolites.
Category C
Category C
Beta-Blocker
Alpha/Beta-Blocker